About Kinvan Private Limited
Data last updated: 27 December 2025
Kinvan Private Limited is a private limited company based in Solan, Himachal Pradesh, India, recognised as a startup by DPIIT. It specialises in api manufacturers, a part of the broader pharmaceuticals sector. Incorporated on 10 October 2020, the company has been in operation for over 6 years.
Registered with ROC Himachal Pradesh under CIN U24100HP2020PTC011851.
Capital: an authorised share capital of ₹410 Cr and a paid-up capital of ₹223.55 Cr. It is led by directors Devang Manharlal Ajmera and Sahebrao Sukhdeo Khilari.
Last AGM: 30 September 2024. Financial statements filed for year ended 31 March 2024. Office: Solan, Himachal Pradesh.
As per the financials filed for FY 2025, the company reported a revenue of ₹135.98 Cr, reflecting significant growth compared to the previous year.
The company has a workforce of approximately 301 employees as per the latest available data.
The company is associated with 2 brands - Dpb Group, Kinvan. As per MCA filings, the company has open charges of ₹181 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website dpbpharma.com.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media**************
-
Registered AddressPlot No.1 Industrial Area, Plassara Tehsil Nalagarh, Solan, Himachal Pradesh, India – 174101
-
IndustryPharma, API Manufacturers
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Kinvan Private Limited
Kinvan Private Limited has one previous CIN (Corporate Identification Number): U24100MH2020PTC347604. The current CIN is U24100HP2020PTC011851, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24100HP2020PTC011851 | Current |
| U24100MH2020PTC347604 | Previous |
Associated Brands with Kinvan Private Limited
Kinvan Private Limited operates two associated brands: DPB Group and Kinvan. These brands represent Kinvan Private Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| DPB Group is engaged in manufacturing pharmaceutical APIs in India. | dpbpharma.com | |
| Manufactures fermentation-based pharmaceutical products for antibiotic resistance. | kinvan.co.in |
Competitors & Alternatives of Kinvan Private Limited
Brands and companies operating in the same space as Kinvan Private Limited include WuXi AppTec, ANI Pharmaceuticals, Aptar and 6 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
WuXi AppTec
|
Provider of CRO and CDMO services | Shanghai, China, China | 2000 |
ANI Pharmaceuticals
|
Branded and generic prescription drugs are developed, manufactured, and marketed. | Baudette, United States, United States | 1996 |
Aptar
|
Regulatory support, brand differentiation, and prototyping services are provided. | Crystal Lake, United States, United States | 1992 |
CHEPLAPHARM
|
Branded pharmaceutical products are developed, marketed, and distributed globally. | Mesekenhagen, Germany, Germany | 1998 |
Red Nucleus
|
Advisory, scientific, and medical communications provided for pharmaceutical industry. | Yardley, United States, United States | 2014 |
Ipsen
|
Biopharmaceutical company focused on developing and commercializing innovative treatments in oncology, rare disease, and neuroscience to improve patient health outcomes | - | 1929 |
Eurofins Scientific
|
Laboratory testing and contract research services are provided globally. | Luxembourg, Luxembourg, Luxembourg | 1987 |
China Medical System
|
Generic formulations including tablets, capsules, liquids, and injectables are manufactured. | Shenzhen, China, China | 1992 |
Aliada Therapeutics
|
Provider of drug research & development services for multiple therapeutic areas | Boston, United States, United States | 2021 |
Business Activity of Kinvan Private Limited
Kinvan Private Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | ********* |
Auditor Details of Kinvan Private Limited
Kinvan Private Limited is audited by Khurana Vineeet & Associates for the financial year 2024. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| Khurana Vineeet & Associates | blur-value | blur-value | blur-value |
Board of Directors of Kinvan Private Limited
Kinvan Private Limited is currently managed by 3 directors, with 4 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Devang Manharlal Ajmera
Also directs:
Kinvan Private Limited, Vardhman Chemtech Limited, Dpb Pharmaceuticals Limited and 1 more
|
Director | 10 Oct 2020 | 5 Years 9 Months | Current |
|
Sahebrao Sukhdeo Khilari
Also directs:
Kinvan Private Limited, Khilari Lifesciences Private Limited, Siddharth Megahomes Private Limited and 2 more
|
Director | 10 Nov 2021 | 4 Years 8 Months | Current |
Financials of Kinvan Private Limited FY 2024 filings available
Kinvan Private Limited reported revenue of ₹135.98 Cr (up 11959% YoY) for FY 2025. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Shareholding Pattern of Kinvan Private Limited
As of FY 2024, Kinvan Private Limited's shareholding pattern shows 100.00% by promoters. The promoters hold a majority stake, indicating strong promoter control.
| Year | 2025 |
|---|---|
| Promoters | 33.19% |
| DII | 23.22% |
| FII | 18.28% |
| Public | 22.89% |
| Others | 2.42% |
Charges & Borrowings of Kinvan Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 16 Apr 2025 | Yes Bank Limited | ₹10 Cr | Open |
| 20 Mar 2023 | Yes Bank Limited | ₹65 Cr | Open |
| 22 Sep 2022 | Hdfc Bank Limited | ₹106 Cr | Open |
Total charge records: 3 View all charges
Employees and EPFO Compliance at Kinvan Private Limited
Kinvan Private Limited has a workforce of 301 employees as of Dec 27, 2025.
Employee Count & EPFO Data of Kinvan Private Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Kinvan Private Limited
GSTIN & GST Filing Data of Kinvan Private Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Kinvan Private Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Kinvan Private Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Kinvan Private Limited
MSME Payment Delays by Kinvan Private Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Kinvan Private Limited
Subsidiaries & Group Companies of Kinvan Private Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Kinvan Private Limited with ownership details.
MCA Filings & Documents of Kinvan Private Limited
MCA Filings & Documents of Kinvan Private Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Kinvan Private Limited
Frequently Asked Questions about Kinvan Private Limited
Kinvan Private Limited is an active private limited company in the pharma sector based in Solan, Himachal Pradesh, India. It was incorporated on 10 October 2020 (6+ years old) and is registered under CIN U24100HP2020PTC011851. The company has 301 employees.
Kinvan Private Limited reported revenue of ₹135.98 Cr for FY 2025 (up 11959.00% YoY).
The current directors of Kinvan Private Limited are:
- Devang Manharlal Ajmera
- Sahebrao Sukhdeo Khilari
- Neha Suresh Khandelwal
The primary industry of Kinvan Private Limited is pharma. The company specifically operates in api manufacturers. The company is currently active in this sector.
Yes, Kinvan Private Limited is recognised as a startup by the Department for Promotion of Industry and Internal Trade (DPIIT).
Kinvan Private Limited can be reached at the registered office: Plot No.1 Industrial Area, Plassara Tehsil Nalagarh, Solan, Himachal Pradesh, India – 174101, or through the website dpbpharma.com.